Three BRICS Launch Generic Challenge For Vertex’s Landmark CF Therapy
Representatives Call Out Originator’s ‘Repeated Strategy Of Stubborn Negotiation’
Executive Summary
With a suite of vastly expensive and advanced cystic fibrosis therapies entirely under its command, Vertex is facing more heat from patients and advocates in several major low- and middle-income countries.